CD79B Antibody

What is CD79B and why is it a significant target for antibody development?

CD79B (also known as B29, Ig-beta) is a transmembrane protein that forms a heterodimer with CD79A (Ig-alpha) as part of the B cell receptor (BCR) complex. This protein plays a crucial role in B cell receptor signaling and is exclusively expressed on B lymphocytes and B cell lymphomas . The significance of CD79B as an antibody target stems from several key characteristics:

• It is a pan-B-cell antigen widely expressed across various mature B-cell malignancies

• CD79B demonstrates rapid internalization when bound by antibodies, making it an excellent vehicle for delivering cytotoxic agents

• Its expression is restricted to B cells among normal tissues, similar to other pan-B-cell antigens like CD19 and CD20

• CD79B contains an immuno-receptor tyrosine-based activation motif (ITAM) that initiates B cell receptor signaling

These properties make CD79B antibodies valuable tools for both diagnostic applications and therapeutic development.

How does CD79B expression vary across different B-cell malignancies?

CD79B expression shows distinct patterns across B-cell malignancies, which has important implications for research and therapeutic targeting:

• High expression is observed in diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), marginal zone lymphoma, Burkitt lymphoma, lymphoplasmacytic lymphoma, and hairy cell leukemia

• Lower expression levels are typically found in chronic lymphocytic leukemia

• Expression is absent in plasma cells

• CD79B expression can be found in both the cytoplasm and on the cell surface, depending on the B-cell maturation state

Researchers should note that CD79B expression in patient samples may need to be validated prior to experimental studies, as expression levels can influence antibody efficacy and experimental outcomes.

What are the optimal conditions for using CD79B antibodies in flow cytometry?

For effective flow cytometric analysis using CD79B antibodies, researchers should consider the following methodological approach:

• Antibody selection: Choose validated clones such as CB3-1 or B29/123 that have demonstrated specificity for CD79B

• Sample preparation: For peripheral blood lymphocytes, use fresh samples when possible and perform standard isolation techniques such as Ficoll gradient separation

• Staining protocol:

  • Use ≤0.5 μg antibody per test (where a test is defined as the amount needed to stain a cell sample in 100 μL final volume)

  • Cell numbers can range from 10⁵ to 10⁸ cells per test, though optimal concentration should be determined empirically

  • For double staining, pair with other B-cell markers such as CD19 for improved identification of B-cell populations

• Controls: Include appropriate isotype controls and consider using CD79B knockout cell lines as negative controls to verify specificity

• Dilution ranges: For unconjugated antibodies like AT107-2, use dilutions of 1:500-1:1,000, with 10μL of diluted antibody to label 1×10⁶ cells in 100μL

A representative flow cytometry analysis can be performed on human peripheral blood lymphocytes using antibodies conjugated to fluorochromes such as PE, FITC, or APC for direct detection .

How can CD79B antibodies be effectively validated for research applications?

Thorough validation of CD79B antibodies is critical for ensuring experimental reliability. A comprehensive validation approach should include:

• Specificity testing:

  • Test against isogenic cell lines with CD79B knock-in or knock-out to confirm target specificity

  • Verify binding to human CD79B with no cross-reactivity to other cell surface proteins

  • For cross-species applications, confirm reactivity across relevant species (many CD79B antibodies work with mouse, human, rat, pig, and other species)

• Application-specific validation:

  • For Western blotting: Confirm band size (~36-40 kDa for mature human CD79B)

  • For immunohistochemistry: Test on known positive tissues (lymphoid tissues) and negative tissues (non-lymphoid tissues)

  • For flow cytometry: Verify staining pattern on B cells versus other lymphocyte populations

• Functional assessment:

  • Evaluate antibody internalization capacity if being used for therapeutic applications

  • Assess effects on B cell receptor signaling if studying functional aspects

• Batch consistency:

  • Compare lot-to-lot variation using standardized positive controls

  • Document antibody performance characteristics across different experiments

This methodical approach ensures reliable and reproducible results when using CD79B antibodies in research contexts.

How do CD79B antibody-drug conjugates (ADCs) compare with other B-cell targeting ADCs?

CD79B antibody-drug conjugates represent an important therapeutic approach for B-cell malignancies, with several distinct advantages and challenges compared to other B-cell targeting ADCs:

Evidence suggests that CD79B ADCs may have advantages over CD79A ADCs, as demonstrated in BJAB xenograft models where anti-CD79b ADCs caused tumor regression while anti-CD79a ADCs only slowed tumor growth . This difference is not explained by affinity or cell surface copy number, as CD79 exists as an obligate heterodimer .

The DCDS0780A conjugate, which consistently attaches two anti-neoplastic molecules per antibody (using THIOMAB technology), showed promising results in clinical studies despite being limited by ocular toxicities at higher doses .

What mechanisms underlie CD79B antibody internalization and how can this be optimized?

CD79B antibody internalization is a critical process for therapeutic efficacy, particularly for antibody-drug conjugates. The mechanisms and optimization strategies include:

• Internalization mechanism:

  • Anti-CD79B antibodies cross-link the B-cell receptor (BCR), triggering internalization

  • This leads to delivery of the BCR-antibody complex to the lysosome-like MIIC compartment

  • In the MIIC compartment, the antibody or ADC is degraded, releasing cytotoxic drugs or metabolites

• Evidence of internalization:

  • In vivo studies show substantial downregulation of surface CD79a and surface IgM following anti-CD79b antibody or ADC treatment

  • Flow cytometry analyses of treated tumors showed homogenous downregulation of IgM and CD79a on the cell surface

  • Immunostaining confirmed antibody penetration throughout tumors with surface IgM internalization

• Optimization strategies:

  • Antibody engineering to enhance cross-linking capacity

  • Selection of linker-drug combinations (like MC-MMAF and MCC-DM1) that remain stable until the ADC reaches lysosomes

  • Targeting epitopes that promote efficient internalization

  • Modulating antibody affinity to balance tumor penetration with receptor occupancy

Understanding these mechanisms helps explain why ADCs targeting other equally abundant B-cell-specific targets that are not directed to the MIIC (e.g., CD21, CD20) may be less effective in lymphoma models .

How can CD79B antibodies be employed in studying treatment resistance mechanisms?

CD79B antibodies provide valuable tools for investigating resistance mechanisms in B-cell malignancies, particularly in the context of CD19-directed therapies:

• Monitoring antigen modulation:

  • Use CD79B antibodies to track changes in BCR complex expression following treatment

  • Flow cytometric analysis can reveal downregulation patterns that may correlate with resistance

  • Compare CD79B with other B-cell markers (CD19, CD20) to identify differential modulation

• Analyzing signaling adaptation:

  • Employ phospho-specific antibodies alongside CD79B antibodies to assess changes in BCR signaling pathways

  • Investigate how alterations in ITAM phosphorylation patterns correlate with treatment response

  • Examine compensatory signaling mechanisms that emerge after targeted therapy

• Patient-derived models:

  • CD79B antibodies can help characterize patient-derived lymphoma cells that have relapsed after CD19 CAR T-cell therapy

  • These models allow for testing of sequential or combination targeting strategies

  • Studies show CD79B CAR T cells exhibit cytotoxic activity against CD19+ and CD19- lymphoma cell lines from patients who relapsed after CD19 CAR therapy

• Genetic analysis correlation:

  • Combine CD79B expression analysis with genetic profiling (mutations, chromosomal alterations)

  • Investigate how CD79B mutational status affects antibody binding and signaling outcomes

These approaches can yield insights into resistance mechanisms and inform the development of more effective sequential or combination therapeutic strategies.

What considerations are important when designing CD79B-targeted CAR T-cell therapies?

Developing effective CD79B-targeted CAR T-cell therapies requires careful design considerations that build upon lessons from other CAR T approaches:

• CAR construct optimization:

  • Testing has shown superior antitumor efficacy with CARs containing CD8α hinge and transmembrane domains, OX40 co-stimulatory domain, and CD3ζ signaling domain

  • The single-chain variable fragment (scFv) selection is critical for specificity and should be derived from highly specific monoclonal antibodies

  • Rigorous validation against CD79B knockout cell lines is essential to confirm specificity

• Potential advantages over CD19 CAR T therapy:

  • Maintained expression in CD19-negative relapse cases

  • Effective against CD19+ and CD19- lymphoma cell lines and patient-derived tumors that relapsed after CD19 CAR T-cell therapy

  • Pan-B-cell expression similar to CD19, making it suitable for various B-cell malignancies

• Monitoring for toxicity and exhaustion:

  • Studies indicate that well-designed CD79B CAR T cells do not demonstrate significant tonic signaling activity or markers of exhaustion

  • Safety profiling should include assessment of on-target, off-tumor effects on normal B cells

  • Expected B-cell aplasia should be managed similar to CD19 CAR T therapy

• Preclinical efficacy data:

  • Novel CD79B CAR T cells have shown high efficiency in eradicating pre-established lymphoma tumors in xenograft models

  • Efficacy has been demonstrated across aggressive lymphoma models including cell line-derived and patient-derived xenografts

These design elements have supported the initiation of clinical trials evaluating CD79B CAR T-cell therapy in patients with relapsed or refractory B-cell lymphomas .

What are the recommended protocols for using CD79B antibodies in immunohistochemistry?

For optimal results when using CD79B antibodies in immunohistochemistry (IHC), researchers should follow these detailed protocols:

• Tissue preparation:

  • Use formalin-fixed, paraffin-embedded (FFPE) tissue sections (4-6 μm thickness)

  • Include positive control tissues (lymph node, spleen) and negative control tissues (non-lymphoid tissues)

  • Antigen retrieval is critical: typically use heat-induced epitope retrieval in citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

• Antibody selection and optimization:

  • Select antibodies validated for IHC such as B29/123 (clone sc-53210)

  • Perform titration experiments to determine optimal concentration

  • Consider using positive control tissues with known high CD79B expression, such as tonsil

• Detection systems:

  • For brightfield microscopy: Use polymer-based detection systems with HRP conjugates

  • For fluorescence: Consider directly conjugated antibodies or use fluorochrome-conjugated secondary antibodies

• Scoring and interpretation:

  • Evaluate membrane and cytoplasmic staining patterns

  • CD79B expression may vary depending on B-cell maturation state

  • Consider using digital image analysis for quantitative assessment

• Multi-marker approaches:

  • For better characterization, consider double staining with CD79B and other B-cell markers

  • This is particularly useful in determining B-cell maturation stages or malignant phenotypes

This protocol can be adapted for frozen sections with appropriate modifications to fixation and antigen retrieval steps.

How should CD79B antibodies be selected for Western blotting applications?

Selecting and optimizing CD79B antibodies for Western blotting requires attention to several technical factors:

• Antibody selection criteria:

  • Choose antibodies specifically validated for Western blotting, such as CB3-1 clone

  • Consider the epitope location - antibodies targeting extracellular domains may require non-reducing conditions to maintain conformational epitopes

  • For human CD79B detection, expected band size is approximately 36-40 kDa for the mature glycoprotein

• Sample preparation optimization:

  • For cell lines: Use RIPA buffer with protease inhibitors

  • For primary tissues: Consider tissue-specific extraction protocols to maintain protein integrity

  • Include positive controls (B-cell lines like Daudi, HBL-1, or SUDHL-6) and negative controls (T-cell lines like Jurkat)

• Technical considerations:

  • Reduce background by:

    • Using milk-based blocking buffers (typically 5% non-fat dry milk)

    • Including appropriate washing steps (TBST buffer with 0.1% Tween-20)

    • Testing different antibody dilutions to optimize signal-to-noise ratio

  • For enhanced detection sensitivity, consider using secondary antibodies conjugated to HRP and ECL detection systems

• Alternative approaches:

  • For low-expression samples, consider immunoprecipitation before Western blotting

  • CD79B antibodies like B29/123 (sc-53210) have been validated for both Western blotting and immunoprecipitation

This methodical approach will help ensure specific detection of CD79B protein in Western blotting applications.

How is CD79B being exploited in bispecific antibody development?

Bispecific antibody development targeting CD79B represents an emerging frontier in immunotherapy research:

• Therapeutic rationale:

  • CD79B has been clinically validated as a safe and effective target for B-cell malignancies through antibody-drug conjugate approaches

  • Bispecific antibodies can leverage CD79B's B-cell specificity while engaging immune effector cells or targeting additional tumor antigens

• T-cell recruiting approaches:

  • T-cell recruiting bispecific antibodies targeting CD79B can harness cytotoxic T-cell potential against B-cell malignancies

  • These approaches may overcome limitations of conventional ADCs by engaging the patient's immune system

• Dual-targeting strategies:

  • Bispecific antibodies targeting both CD79B and CD19 could potentially address CD19 antigen loss/downregulation

  • This approach may reduce resistance mechanisms seen with single-target therapies

  • The rapid internalization property of CD79B antibodies can be exploited for enhanced delivery of cytotoxic payloads

• Technical advantages of bispecific ADCs:

  • Fast internalization to lysosomal compartments improves payload delivery

  • B-cell restricted expression minimizes off-target toxicity

  • Dual targeting may enhance binding avidity and improve tumor penetration

Creative Biolabs and other research organizations are developing novel bispecific ADCs targeting CD79B, which may provide more effective treatment options for B-cell malignancies .

What are the emerging applications of CD79B stable cell lines in research?

CD79B stable cell lines are becoming increasingly valuable research tools for advancing both basic science and therapeutic development:

• Antibody development and screening:

  • CHO/Human CD79B Stable Cell Lines engineered to express full-length human CD79B serve as valuable tools for cell-based CD79B binding assays

  • These cell lines facilitate high-throughput screening of novel antibody candidates

  • Expression analysis using flow cytometry with APC-labeled anti-human CD79B antibodies can confirm stable expression

• Therapeutic validation:

  • Stable cell lines provide consistent targets for evaluating antibody specificity and binding characteristics

  • They serve as critical tools for:

    • ADC internalization studies

    • Cytotoxicity assays

    • Bispecific antibody functional testing

• Mechanistic studies:

  • CD79B-expressing cell lines paired with CD79B knockout counterparts enable detailed investigation of:

    • BCR complex assembly and signaling

    • Antibody-induced receptor downregulation

    • Internalization mechanisms and kinetics

• Future applications:

  • Development of reporter cell lines with CD79B expression linked to fluorescent or luminescent readouts

  • Creation of inducible expression systems to study dose-dependent effects

  • CRISPR-engineered variant cell lines to study effects of CD79B mutations or polymorphisms

These stable cell line resources significantly accelerate research by providing standardized experimental systems for studying CD79B biology and developing targeted therapeutics .

How can researchers address non-specific binding issues with CD79B antibodies?

Non-specific binding can significantly impact experimental results when using CD79B antibodies. Here are methodological approaches to minimize this issue:

• Optimizing blocking conditions:

  • For flow cytometry: Use 2-5% BSA or FBS in PBS for at least 30 minutes before antibody incubation

  • For IHC/ICC: Extend blocking time (60 minutes) with specialized blocking buffers containing both proteins and detergents

  • For Western blotting: Use 5% non-fat dry milk or BSA in TBST for at least 1 hour

• Antibody dilution optimization:

  • Perform titration experiments to determine the optimal concentration for your application

  • For flow cytometry, start with recommended dilutions (e.g., 1:500-1:1,000 for antibodies like AT107-2)

  • Higher antibody concentrations often increase non-specific binding

• Validation controls:

  • Include isotype controls matched to your primary antibody's host species and isotype

  • Use CD79B knockout cell lines as negative controls

  • Include competitive blocking with the immunizing peptide where available

• Technical modifications:

  • Add 0.1-0.3% Triton X-100 or Tween-20 to washing buffers to reduce hydrophobic interactions

  • Consider pre-adsorption of antibodies against tissues or cells from species with potential cross-reactivity

  • Increase washing duration and volume after antibody incubation

• Antibody selection:

  • Choose antibodies with documented specificity, such as those tested against isogenic cell lines with CD79B knock-in or knock-out

  • Consider monoclonal antibodies (like B29/123 or CB3-1) which typically show higher specificity than polyclonal alternatives

Implementing these approaches systematically can significantly improve signal-to-noise ratio and experimental reliability.

What strategies can improve detection of CD79B in samples with low expression levels?

Detecting CD79B in samples with low expression presents technical challenges that require specialized approaches:

• Signal amplification techniques:

  • For IHC/ICC: Employ tyramide signal amplification (TSA) systems, which can increase sensitivity by 10-100 fold

  • For flow cytometry: Use secondary antibodies with higher fluorochrome-to-protein ratios or brightness

  • For Western blotting: Consider chemiluminescent substrates with enhanced sensitivity or use biotin-streptavidin amplification

• Sample enrichment methods:

  • For cell populations: Use magnetic bead separation to enrich B cells before analysis

  • For protein detection: Consider immunoprecipitation to concentrate CD79B before Western blotting

  • CD79B antibodies like B29/123 (sc-53210) have been validated for immunoprecipitation applications

• Optimized antibody selection and protocols:

  • Choose high-affinity antibodies specifically validated for detecting low abundance targets

  • Increase primary antibody incubation time (overnight at 4°C) to enhance binding

  • Reduce washing stringency slightly to preserve weak signals

• Technical instrumentation adjustments:

  • For flow cytometry: Optimize PMT voltages and compensation to detect dim populations

  • For imaging: Use confocal microscopy with increased laser power and detector sensitivity

  • For Western blotting: Extend film exposure times or use more sensitive digital imaging systems

• Alternative detection approaches:

  • Consider PCR-based methods to detect CD79B at the mRNA level

  • RNAscope or similar in situ hybridization techniques can provide single-molecule sensitivity

  • Mass cytometry (CyTOF) using metal-conjugated antibodies can offer enhanced sensitivity for rare populations

These approaches can be combined as needed based on the specific research context and sample limitations.

How might CD79B antibodies contribute to overcoming resistance in B-cell malignancy treatments?

CD79B antibodies show significant promise in addressing treatment resistance in B-cell malignancies through several mechanisms:

• Targeting CD19-negative relapses:

  • CD79B remains expressed in many B-cell malignancies that have lost CD19 expression after CD19-targeted therapies

  • CD79B CAR T cells have demonstrated robust cytotoxic activity against both CD19+ and CD19- lymphoma cell lines derived from patients who relapsed after CD19 CAR T-cell therapy

  • This provides a rational sequential targeting approach for relapsed disease

• Combination therapy approaches:

  • CD79B antibodies or ADCs can be combined with other therapeutic modalities:

    • Rituximab (anti-CD20) combinations have been tested clinically

    • Combination with BTK inhibitors could provide complementary targeting of B-cell receptor signaling

    • Integration with immune checkpoint inhibitors might enhance anti-tumor immune responses

• Novel antibody engineering:

  • Development of bispecific antibodies targeting both CD79B and other B-cell antigens could prevent escape through single antigen loss

  • Next-generation ADCs with novel payloads might overcome resistance mechanisms

  • Antibody formats with enhanced tissue penetration could improve efficacy in solid tumor contexts

• Precision medicine applications:

  • CD79B expression analysis could guide patient selection for targeted therapies

  • Molecular profiling combined with CD79B status might identify optimal therapeutic combinations

  • Real-time monitoring of CD79B modulation during treatment could inform adaptive therapeutic strategies

Clinical evidence supporting these approaches includes the DCDS0780A phase 1 study, which demonstrated a 47% response rate in heavily pretreated B-NHL patients, including 28% complete responses and 18% partial responses .

What are the key considerations for developing next-generation CD79B-targeted therapeutics?

The development of next-generation CD79B-targeted therapeutics requires addressing several critical considerations:

• Optimization of drug-to-antibody ratio (DAR) and conjugation chemistry:

  • THIOMAB technology allows for consistent conjugation of two anti-neoplastic molecules per antibody, in contrast to heterogeneous loading

  • While this approach enabled testing at higher doses, ocular toxicities were observed, indicating potential limitations to therapeutic index expansion

  • Advanced site-specific conjugation methods may further improve stability and pharmacokinetics

• Novel payload selection:

  • Current ADCs primarily utilize microtubule-disrupting agents like MMAE

  • DNA-damaging agents, RNA polymerase inhibitors, or immunomodulatory payloads may offer alternatives

  • Payload mechanisms less affected by common resistance pathways could improve durability of response

• Addressing toxicity profiles:

  • Ocular toxicities were dose-limiting in DCDS0780A clinical trials

  • Strategic payload selection and linker chemistry optimization may help mitigate toxicity

  • Novel delivery approaches or dosing schedules could improve therapeutic window

• Pharmacokinetic considerations:

  • DCDS0780A showed a linear pharmacokinetic profile at doses ≥1.2 mg/kg

  • Understanding target-mediated drug disposition is critical for optimizing dosing

  • Monitoring antibody internalization rates and payload release kinetics

• Rational combination strategies:

  • Identifying synergistic combinations with other therapeutic modalities

  • Temporal sequencing of treatments to maximize efficacy and minimize resistance

  • Biomarker-guided patient selection for specific combination approaches

The encouraging anti-tumor activity observed with current CD79B-targeted therapeutics provides strong rationale for continued investigations into novel antibody technologies and targeting strategies .